妊娠女性治疗性恰加斯病疫苗预防先天性传播的潜在经济价值
研究用计算决策模型模拟墨西哥恰加斯病阳性孕妇所生婴儿的临床结局与检测策略,评估不同效力治疗性疫苗的经济价值。相比不接种,25%、50%、75%效力疫苗每万名感染孕妇分别避免125、251、376例先天病例;并测算各效力疫苗具成本效果与成本节约的疫苗价格阈值。
要点
- 25%效力疫苗每万名感染孕妇避免125例先天病例、1.9例婴儿死亡、78个DALY。
- 50%效力疫苗每万名感染孕妇避免251例先天病例、3.8例婴儿死亡、160个DALY。
- 75%效力疫苗每万名感染孕妇避免376例先天病例、5.8例婴儿死亡、238个DALY。
核心结论
- 研究界定了对恰加斯病阳性孕妇行治疗性接种具成本效果与成本节约的价格阈值,为决策者开发和上市该疫苗提供经济参考。
研究设计与样本
- 计算决策模型,模拟墨西哥恰加斯病阳性孕妇所生婴儿的临床结局与诊断检测策略,并评估接种影响。
主要发现
- 相比不接种,25%效力疫苗每万名感染孕妇避免125例(95%不确定性区间122-128)先天病例、1.9例(95%不确定性区间1.6-2.2)婴儿死亡和78个(95%不确定性区间66-91)DALY。
- 相比不接种,50%效力疫苗每万名感染孕妇避免251例(95%不确定性区间248-254)先天病例、3.8例(95%不确定性区间3.6-4.2)婴儿死亡和160个(95%不确定性区间148-171)DALY。
- 相比不接种,75%效力疫苗每万名感染孕妇避免376例(95%不确定性区间374-378)先天病例、5.8例(95%不确定性区间5.5-6.1)婴儿死亡和238个(95%不确定性区间227-249)DALY。
关键数值与推荐
- 25%效力疫苗在疫苗价格≤240美元(第三方付款人视角)和≤310美元(社会视角)时具成本效果(增量成本效果比<墨西哥人均国内生产总值的3倍,即<每避免1个DALY 29698美元),在≤10美元和≤80美元时成本节约。
- 50%效力疫苗在疫苗价格≤490美元(第三方付款人视角)和≤615美元(社会视角)时具成本效果,在≤25美元和≤160美元时成本节约。
- 75%效力疫苗在疫苗价格≤720美元(第三方付款人视角)和≤930美元(社会视角)时具成本效果,在≤40美元和≤250美元时成本节约。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, there are no solutions to prevent congenital transmission of Chagas disease during pregnancy, which affects 1-40% of pregnant women in Latin America and is associated with a 5% transmission risk. With therapeutic vaccines under development, now is the right time to determine the economic value of such a vaccine to prevent congenital transmission. METHODS: We developed a computational decision model that represented the clinical outcomes and diagnostic testing strategies for an infant born to a Chagas-positive woman in Mexico and evaluated the impact of vaccination. RESULTS: Compared to no vaccination, a 25% efficacious vaccine averted 125 [95% uncertainty interval (UI): 122-128] congenital cases, 1.9 (95% UI: 1.6-2.2) infant deaths, and 78 (95% UI: 66-91) DALYs per 10,000 infected pregnant women; a 50% efficacious vaccine averted 251 (95% UI: 248-254) cases, 3.8 (95% UI: 3.6-4.2) deaths, and 160 (95% UI: 148-171) DALYs; and a 75% efficacious vaccine averted 376 (95% UI: 374-378) cases, 5.8 (95% UI: 5.5-6.1) deaths, and 238 (95% UI: 227-249) DALYs. A 25% efficacious vaccine was cost-effective (incremental cost-effectiveness ratio <3× Mexico's gross domestic product per capita, <$29,698/DALY averted) when the vaccine cost ≤$240 and ≤$310 and cost-saving when ≤$10 and ≤$80 from the third-party payer and societal perspectives, respectively. A 50% efficacious vaccine was cost-effective when costing ≤$490 and ≤$615 and cost-saving when ≤$25 and ≤$160, from the third-party payer and societal perspectives, respectively. A 75% efficacious vaccine was cost-effective when ≤$720 and ≤$930 and cost-saving when ≤$40 and ≤$250 from the third-party payer and societal perspectives, respectively. Additionally, 13-42 fewer infants progressed to chronic disease, saving $0.41-$1.21 million to society. CONCLUSION: We delineated the thresholds at which therapeutic vaccination of Chagas-positive pregnant women would be cost-effective and cost-saving, providing economic guidance for decision-makers to consider when developing and bringing such a vaccine to market.
引用
- Bartsch SM, Stokes-Cawley OJ, Buekens P, et al. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020. PMID: 32171575. doi:10.1016/j.vaccine.2020.02.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。